

Interaction Report

Report ID: zeny
Date Produced: 11 July 2025

Antiretroviral Treatment

Abacavir (ABC)
Lamivudine (3TC)
Raltegravir (RAL)

Co-medications

Atenolol
Bisoprolol
Carvedilol
Metoprolol
Nebivolol
Oxprenolol
Pindolol
Propranolol
Timolol

This report lists the summaries of potential interactions (i.e. "red", "amber" and "yellow" classifications) for the drugs in the table above.

Interactions with a "green" or "grey" classification (i.e. no clinically significant interaction or no clear data) have been checked and are listed at the end of this report, but summaries are not shown.

For full details of all interactions, see www.hiv-druginteractions.org.

Description of the interactions

Potential weak interaction - additional action/monitoring or dosage adjustment is unlikely to be required (YELLOW)

Lamivudine (3TC) + Atenolol

Coadministration has not been studied. Atenolol is mainly eliminated unchanged by the kidney, both by glomerular filtration and active secretion via the renal transporters OCT2 and MATE1. There is potential for competition with lamivudine for elimination via renal transport proteins, which may lead to increased concentrations of either drug.

No clinically significant interaction expected (GREEN)

Abacavir (ABC) + Nebivolol

Lamivudine (3TC) + Nebivolol

Raltegravir (RAL) + Nebivolol

Abacavir (ABC) + Atenolol

Raltegravir (RAL) + Atenolol

Lamivudine (3TC) + Bisoprolol

Abacavir (ABC) + Bisoprolol

Raltegravir (RAL) + Bisoprolol

Lamivudine (3TC) + Carvedilol

Abacavir (ABC) + Carvedilol

Raltegravir (RAL) + Carvedilol

Lamivudine (3TC) + Metoprolol

Abacavir (ABC) + Metoprolol
Raltegravir (RAL) + Metoprolol
Lamivudine (3TC) + Propranolol
Abacavir (ABC) + Propranolol
Raltegravir (RAL) + Propranolol
Abacavir (ABC) + Timolol
Lamivudine (3TC) + Timolol
Raltegravir (RAL) + Timolol
Lamivudine (3TC) + Oxprenolol
Raltegravir (RAL) + Oxprenolol
Abacavir (ABC) + Oxprenolol
Raltegravir (RAL) + Pindolol
Abacavir (ABC) + Pindolol
Lamivudine (3TC) + Pindolol